Top five enriched GO terms in Antonio and Colorado under HNT with MCP application. by Wardah K. Mustahsan (17484456)

Subjects:

Lists of differentially expressed genes for the interaction between high night-time temperature and 1-MCP treatments. by Wardah K. Mustahsan (17484456)

Subjects:

The expression differences of ethylene-related genes and transcription factors caused by MCP effect under HNT. by Wardah K. Mustahsan (17484456)

Subjects:

Heat and stress-related transcription factors under 1-MCP and HNT interaction effect in Antonio. by Wardah K. Mustahsan (17484456)

Subjects:

Lists of differentially expressed genes and gene ontology (GO) enrichment analysis under ambient versus high night-time temperatures with 1-MCP application. by Wardah K. Mustahsan (17484456)

Subjects:

The expression differences of ethylene-related genes and transcription factors of HNT effect with MCP application. by Wardah K. Mustahsan (17484456)

Subjects:

Gene ontology (GO) enrichment analysis under high night-time temperatures with and without 1-MCP application. by Wardah K. Mustahsan (17484456)

Subjects:

S1 File - by Luqiong Liu (11537092)

“…Compared with LPS treatment alone, BA significantly mitigated the reduction in the TEER, decreased FD-4 flux permeability, increased the mRNA expression of ZO-1 and Occludin, and normalized the distribution of ZO-1 and Occludin in Caco2 cells. …”

Experimental treatments and groups. by Luqiong Liu (11537092)

“…Compared with LPS treatment alone, BA significantly mitigated the reduction in the TEER, decreased FD-4 flux permeability, increased the mRNA expression of ZO-1 and Occludin, and normalized the distribution of ZO-1 and Occludin in Caco2 cells. …”

Primers for RT-qPCR. by Luqiong Liu (11537092)

“…Compared with LPS treatment alone, BA significantly mitigated the reduction in the TEER, decreased FD-4 flux permeability, increased the mRNA expression of ZO-1 and Occludin, and normalized the distribution of ZO-1 and Occludin in Caco2 cells. …”

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during letrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Flowchart of patient selection in this study. by Kazuyoshi Ohkawa (836847)

Subjects:

Changes in the FIB-4 index in breast cancer patients with a FIB-4 index of ≥ 2.67 during letrozole and anastrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Changes in the liver fibrosis-related markers in breast cancer patients with a FIB-4 index of >2.30 during anastrozole treatment. by Kazuyoshi Ohkawa (836847)

Subjects:

Clinical features and cancer treatment in patients with breast cancer receiving letrozole and anastrozole. by Kazuyoshi Ohkawa (836847)

Subjects:

S1 Data - by Kazuyoshi Ohkawa (836847)

Subjects:

Clinical course of patient no. by Kazuyoshi Ohkawa (836847)

Subjects:

Socio-demographic and medical characteristics of patients with liver cancer. by Ayana Ablayeva (22103708)

Subjects:

Data cleaning and preparation algorithm. by Ayana Ablayeva (22103708)

Subjects:

Upcycling of Postconsumer Recyclate Polypropylene into Low Warping and High Toughness 3D Printable Filaments by Animesh Gopal (18521180)

Subjects: